The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

For many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...

Notably, there has been speculation about a potential acquisition of SpringWorks by Merck (NSE:PROR) KGaA. Analysts view this potential acquisition as strategically sound for several reasons ...

Notably, there has been speculation about a potential acquisition of SpringWorks by Merck (NSE:PROR) KGaA. Analysts view this potential acquisition as strategically sound for several reasons: 1. There ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cheap high dividend stocks. According to Deutsche Bank Wealth Management, the global ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...